Instability of Acylcarnitines in Stored Dried Blood Spots: The Impact on Retrospective Analysis of Biomarkers for Inborn Errors of Metabolism

Willemijn J. van Rijt 1, Peter C. J. I. Schielen 2, Yasemin Özer 3, Klaas Bijsterveld 3, Fjodor H. van der Sluijs 3, Terry G. J. Derks 1 and M. Rebecca Heiner-Fokkema 3,*

1 Section of Metabolic Diseases, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands; w.j.van.rijt@umcg.nl (W.J.v.R.); t.g.j.derks@umcg.nl (T.G.J.D.)

2 Reference Laboratory for Neonatal Screening, Centre for Health Protection, National Institute for Public Health and the Environment, 3721 BA Bilthoven, The Netherlands; peter.schielen@rivm.nl

3 Laboratory of Metabolic Diseases, Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands; y.ozer@umcg.nl (Y.Ö.); k.bijsterveld@umcg.nl (K.B.); f.van.der.sluijs@umcg.nl (F.H.v.d.S.)

* Correspondence: m.r.heiner@umcg.nl

Received: 18 September 2020; Accepted: 27 October 2020; Published: 2 November 2020

Abstract: Stored dried blood spots (DBS) can provide valuable samples for the retrospective diagnosis of inborn errors of metabolism, and for validation studies for newborn blood spot screening programs. Acylcarnitine species are subject to degradation upon long-term storage at room temperature, but limited data are available on the stability in original samples and the impact on acylcarnitine ratios. We analysed complete acylcarnitine profiles by flow-injection tandem mass spectrometry in 598 anonymous DBS stored from 2013 to 2017, at +4 °C during the first year and thereafter at room temperature. The concentrations of C2-, C3-, C4-, C5-, C6-, C8-, C10:1-, C10-, C12:1-, C12-, C14:1-, C14-, C16:1-, C16-, C18:2-, C18:1-, C18-, C5OH C4DC-, C18:1OH-, and C16DC-carnitine decreased significantly, whereas a positive trend was found for free carnitine. Only the C4/C8-, C8/C10-, C14:1/C10- and C14:1/C16-carnitine ratios appeared robust for the metabolite instability. The metabolite instability may provoke the wrong interpretation of test results in the case of retrospective studies and risk the inaccurate estimation of cut-off targets in validation studies when only stored control DBS are used. We recommend including control DBS in diagnostic, retrospective cohort studies, and, for validation studies, we recommend using fresh samples and repeatedly re-evaluating cut-off targets.

Keywords: acylcarnitine; dried blood spot; inborn error of metabolism; metabolite instability; metabolite stability; newborn blood spot screening; retrospective diagnosis; storage; tandem mass spectrometry

1. Introduction

The development of tandem mass spectrometry (MS/MS) enabled rapid determination of acylcarnitine and amino acid profiles [1,2]. This technique is commonly used in population newborn bloodspot screening (NBS) to screen for disorders of mitochondrial fatty acid oxidation, and organic acid and amino acid metabolism [3]. The primary process of NBS programs (e.g., screening panel, sampling window, analytical techniques, storage time of filter paper cards and storage conditions) varies worldwide, and even within countries [4,5]. In The Netherlands, 17 inborn errors of metabolism...
(IEM) are currently included in the NBS program [6]. The dried blood spots (DBS) on filter paper cards are generally stored for a maximum period of five years after laboratory analysis [6].

Many IEMs are associated with unexpected death in early childhood, resulting from energy deficiency or intoxication [7]. The often non-specific clinical presentations imply a risk of IEMs to remain unrecognized as cause of death. Stored DBS can provide a valuable sample for post-mortem investigations after unexpected death in early childhood [8–10]. This especially holds for countries, where only a limited selection of IEMs is included in the NBS program and/or diagnostic resources are scarce [4]. Moreover, stored DBS can be used for the evaluation of biomarkers of IEMs considered to be included in the NBS program [11].

A study we recently performed on the prevalence of IEMs in children who died in early childhood, using metabolite analysis in stored DBS, was complicated by the impact of long-term storage on the acylcarnitine profiles. While the stability of C3DC-, C5DC-carnitine and saturated acylcarnitine species has been analysed in stored, spiked DBS [12,13], the available data on acylcarnitine concentrations in stored, original DBS are limited and only concern the stability of C3DC-, C0-, C2-, C3, C4, and C5-carnitine [14–16]. Besides, the impact of metabolite stability on acylcarnitine ratios, which can be used for diagnostic differentiation and characterization of IEMs [3], has never been assessed. Hence, we systematically analysed the complete acylcarnitine profiles in original DBS stored from 2013 to 2017. Here, we report how metabolite instability can complicate the interpretation of retrospectively analysed acylcarnitine biomarkers for IEMs in stored DBS, and reflect on the potential risks of using control DBS stored at room temperature for validation studies for NBS programs.

2. Materials and Methods

The Medical Ethical Committee of the University Medical Center Groningen (Groningen, The Netherlands) confirmed that the Medical Research Involving Human Subjects Act did not apply and that official approval of this study by the Medical Ethical Committee was not required (METc code 2016/694). The Dutch NBS program is regulated by the National Institute for Public Health and the Environment (Bilthoven, The Netherlands) (RIVM in Dutch). Its Research Committee on Neonatal Screening (WONHS in Dutch) authorized the study. A waiver of consent was granted by both the METc and WONHS, since the study concerned anonymized samples.

In The Netherlands, neonatal blood, sampled from the heel, is spotted on filter paper cards between 72 and 168 h after birth and subsequently analysed in one of the five regional screening laboratories, according to national protocols [6]. All filter paper cards were stored at +4 °C for one year at the respective regional screening laboratory for quality assurance purposes. If authorized by the parents, the filter paper cards were stored at room temperature for another four years at the central archive of the RIVM reference laboratory, for quality assurance purposes and anonymized retrospective biomarker studies. There was no conditioning of humidity. The cards were stored in sealed bags (200–300 per bag) in cardboard boxes (20–30 bags per box). Once a year, in January of calendar year “X”, all filter paper cards of calendar year “X-6” are destroyed [6]. If the parents object to the use of residual anonymized blood samples for scientific research, the filter paper card is destroyed after one year.

This study is part of a larger research project on the prevalence of IEMs in children who died in early childhood. DBS included in the current study were from children with normal NBS results (i.e., control samples in the aforementioned study). In October 2018 (start of study), the available stored filter paper cards dated back to 2013. A total of 120 anonymized DBS on filter paper cards per complete storage year, i.e., 2013 to 2017, were retrieved from the storage facilities of the RIVM, resulting in five storage year cohorts (i.e., 2013, 2014, 2015, 2016 and 2017). Until analyses, the DBS were kept in sealed bags with freshly added silica sachets, stored in a refrigerator at the laboratory of Metabolic Diseases in Groningen, the Netherlands. The number of spots per year cohort, i.e., 120, permits the nonparametric determination of reference intervals [17,18]. Filter paper cards of children whose parents did not authorize the use for anonymous research purposes were excluded.
Flow-injection MS/MS analysis was used to quantitatively determine the acylcarnitine profiles in the DBS. Three 3.2 mm Ø discs were punched out of the DBS. Acylcarnitines were extracted by vortexing for 30 min at 600 rpm after the addition of 6 deuterium-labeled internal standards in methanol/MilliQ H2O (80/20 v/v). Supernatant was transferred to a vial and analyzed by flow-injection tandem-mass spectrometry (Sciex API4500, Framingham, MA, USA). Concentrations of C0 and the individual acylcarnitines were quantified by multiple reaction monitoring. C0 by an m/z transition of 162 ≥ 103 and acylcarnitines by selected precursor ions with m/z 85 as the common product ion, as described previously [19]. Data evaluation was performed with Analyst® MD 1.6.2 Instrument Control and Data Processing Software (Sciex, Framingham, MA, USA). The measurements took place between November 2018 and July 2019. Quality control specimens were analysed parallel with the study samples to monitor the precision during the study period. Concentrations were expressed in micromole per liter, with two decimal places.

Data analysis was performed using SIMCA Software, version 15.0.2 (Umetrics, Umea, Sweden), Microsoft Excel with the Analyse-it add-in, version 4.81.6, and IBM SPSS Statistics for Windows, version 23 (IBM Corporation, Armonk, NY, USA). GraphPad Prism, version 5.0 (GraphPad Software, La Jolla, CA, USA) was used to create graphs. First, a principal component analysis was used to visualize and explore the complete dataset. Cases outside the 99% Hotelling’s T² range were identified as strong outliers and excluded from further data analysis. Next, the distributions of the acylcarnitine concentrations and their molar ratios per storage year cohort were assessed. Jonckheere’s trend test was used to test for significant trends upon storage duration, a p-value of <0.05 was considered statistically significant. The test was not applied when >50% of the cases had concentrations at or below the detection limit (i.e., <0.01–0.05, depending on acylcarnitine species investigated), when >50% of the cases concerned zero or infinite values for molar ratios, or when a visual trend was absent. For the acylcarnitine species with a significant change in the concentration upon long-term storage, regression analysis was used to define the trend. For linear trends, the annual decay rates were estimated from the slope of the trend line equations. The four-year percent decays were calculated from the estimated decay rates and the median acylcarnitine concentrations in 2017. For other trend types, we calculated the four-year percent decays from the difference in the median concentrations in 2017 and 2013. Finally, we evaluated the possible consequences of metabolite instability for adequate interpretation of acylcarnitine biomarkers for IEMs upon long-term storage room temperature. To this aim, we investigated the potential impact on (1) retrospective MS/MS analysis in stored DBS for the detection of IEMs, and (2) validation studies in stored control DBS to determine cut-off targets for NBS programs.

3. Results

A total of 598 DBS were analysed; 119 DBS from storage years 2013 and 2014 and 120 DBS from storage years 2015–2017. The data of the low- and high-quality control samples per acylcarnitine species are depicted in Table S1. The mean inter-assay coefficient of variation was <20% for all acylcarnitine species, except for some acylcarnitines (i.e., unsaturated-, hydroxy-, dicarboxylic, and very long-chain acylcarnitine species) with concentrations close to the detection limit. Upon outlier detection via principal component analysis (n = 598, four components, UV scaling, cumulative R2X = 0.536; cumulative Q2 = 0.373), 20 cases were excluded from the dataset (i.e., 2014: n = 6/119; 2015: n = 6/120; 2016: n = 1/120; 2017: n = 7/120).

The changes in carnitine and acylcarnitine concentrations per storage year cohort are presented in Figure 1. Jonckheere’s trend test revealed a significant negative trend upon long-term storage for C2-, C3-, C4-, C5-, C6-, C8-, C10:1-, C10-, C12:1-, C12-, C14:1-, C14-, C16:1-, C16-, C18:2-, C18:1-, C18-, C5OH + C4DC-, C18:1OH-, and C16DC-carnitine concentrations. A positive trend was found for free carnitine. The total carnitine concentration (i.e., the sum of acylcarnitines plus free carnitine) did not change upon long-term storage.
Using regression analysis, the trend type for free carnitine was defined as polynomial, whereas, for C2- and C3-carnitine the trend appeared exponential. For the remaining acylcarnitine species, the trend was defined as linear. The estimated decays of the acylcarnitine species are presented in Table S2. The observed decreases in absolute concentrations between 2017 and 2013 were greatest for C2-, C3-, C16-, C18:1, C18-carnitine. The most substantial percentual drop in concentrations was found for C2-, C3-, C6-, C5OH + C4DC-, and C18:1OH-carnitine, with estimated four-year decays above 60%. The estimated four-year decay ranged between 22% and 34% for the remaining saturated acylcarnitines, and between 30% and 45% for the unsaturated acylcarnitines and C16DC-carnitine.

Figure 1. Cont.
Figure 1. Cont.
Figure 1. Changes in carnitine and acylcarnitine concentrations. The impact of metabolite instability upon long-term storage at room temperature. The boxplots represent the first quartile, median and third quartile. The whiskers extend to the 2.5th and 97.5th percentiles. Individual dots represent non-extreme outliers. Shaded areas represent the reference ranges as determined by our centre for the neonatal population. For C5:1-, C12OH-, C14OH-, C16OH-, and C18OH-, C6DC-, C16DC-, C18DC-, C24-, and C26-carnitine, the upper reference limit is below the detection limit (i.e., not detectable). * Statistically significant trend in the concentration upon storage duration, as determined by Jonckheere’s trend test. The following parameters were excluded from statistical analysis: C5:1-, C4OH + C3DC-, C5DC-, C6DC-, C12OH-, C14OH-, C16OH-, C18OH-, C18DC-, C24-, and C26-carnitine.

The impact of long-term storage on the molar ratios of acylcarnitine species is depicted in Figure 2. The C14:1/C12:1 ratio was excluded from statistical analysis because of infinite values in >50% of the data entries. Only the C4/C8-, C8/C10-, and C14:1/C16-carnitine ratios did not demonstrate a significant trend upon long-term storage, as determined by Jonckheere’s trend test. The C14:1/C10-carnitine ratio, though statistically significant, did not show a visual trend. The percentual decays of the individual acylcarnitines in these ratios were similar (i.e., the absolute difference in the estimated percent decays was <5%). Therefore, these ratios were assessed as robust with regard to the impact of metabolite instability upon long-term storage at room temperature.

Figure 2. Cont.
Figure 2. Changes in the molar ratios of carnitine and acylcarnitines. The impact of metabolite instability upon long-term storage at room temperature. The boxplots represent the first quartile, median and third quartile. The whiskers extend to the 2.5th and 97.5th percentiles. Individual dots represent non-extreme outliers. Shaded areas represent the reference ranges as determined by our centre for the neonatal population. For C14:1/C12:1, no reference range is available because of too many infinite values. For C16OH/C16 and C18OH/C18, the upper reference limit is 0.0. * Statistically significant trend in the molar ratio upon storage duration, as determined by Jonckheere’s trend test. The following ratios were excluded from statistical analysis: C5/C0-, C14:1/C12:1-, C16OH/C16- and C18OH/C18-carnitine.

The metabolite instability increases the likelihood of wrong interpretation of acylcarnitine biomarkers for IEMs in DBS stored at room temperature. Tables 1 and 2 present the potential risks for the detection of IEMs upon retrospective MS/MS analysis, and for validation studies in stored control DBS to determine cut-off targets for NBS programs.
### Table 1. Potential impact of metabolite instability on the interpretation of carnitine and acylcarnitine concentrations.

| Parameter | Disorder | Retrospective Analysis of IEMs | Validation Studies for NBS Programs |
|-----------|----------|-------------------------------|-------------------------------------|
| C0 (low)  | CUD      | False-negative                | Too high                           |
| C0 (high) | CPT-I    | False-positive                | Too high                           |
| C2 (low)  | CUD, CPT-II | False-positive              | Too low                            |
| C3 (low)  | CUD      | False-positive                | Too low                            |
| C3 (high) | PROP, MUT, Cbl A-D | False-negative          | Too low                            |
| C4        | SCAD, EE, IBG, FIGLU \(^a\), MADD | False-negative          | Too low                            |
| C5        | IVA, MADD, 2MBG, EE | False-negative          | Too low                            |
| C6        | MCAD, MADD | False-negative              | Too low                            |
| C8        | MCAD, MADD | False-negative              | Too low                            |
| C10:1     | MCAD     | False-negative                | Too low                            |
| C10       | MADD, MCAD | False-negative              | Too low                            |
| C12:1     | MADD, VLDAD | False-negative              | Too low                            |
| C12       | MADD, CPT-II, CACT, VLDAD | False-negative          | Too low                            |
| C14:1     | VLDAD, MADD, LCHAD/TFP | False-negative          | Too low                            |
| C14       | MADD, CPT-II, VLDAD, CACT, LCHAD/TFP | False-negative          | Too low                            |
| C16:1     | CACT, CPT-II | False-negative              | Too low                            |
| C16 (low) | CPT-I, CUD | False-positive                | Too low                            |
| C16 (high)| CACT, CPT-II | False-negative              | Too low                            |
| C18:2 (low)| CPT-I | False-positive                | Too low                            |
| C18:2 (high)| CPT-II, CACT | False-negative          | Too low                            |
| C18:1 (low)| CPT-I, CUD | False-positive                | Too low                            |
| C18:1 (high)| CPT-I, CACT | False-negative              | Too low                            |
| C18 (low) | CPT-I, CUD | False-positive                | Too low                            |
| C18 (high)| CPT-II, CACT | False-negative              | Too low                            |
| C5OH + C4DC | 3MCC, HMG, MCD, 3MGA, BTD, BKT, 2M3HBA | False-negative          | Too low                            |
| C18:1OH   | LCHAD/TFP | False-negative                | Too low                            |
| C16DC     | PBD      | False-negative                | Too low                            |

The potential consequences associated with (1) the interpretation of retrospectively analysed carnitine and acylcarnitine concentrations in DBS upon long-term storage at room temperature for the detection of IEMs, and (2) using control DBS stored at room temperature for validation studies on cut-off targets for NBS programs.

\(^a\) FIGLU is only associated with a high C4-carnitine when butylation is applied. Abbreviations (in alphabetical order): 2M3HBA, 2-methyl-3-hydroxybutyric aciduria (i.e., alpha-methylacetooacetic aciduria; online mendelian inheritance in man (OMIM) #203750); 2MBG, 2-short/branched chain acyl-CoA dehydrogenase deficiency (# 610006); 3MCC, 3-methylcrotonyl-CoA carboxylase deficiency (#210200, #210210); 3MGA, 3-methylglutaconic aciduria (#250950, #302060); BKT, beta-ketothiolase deficiency (#203750); BTD, biotinidase deficiency (#253260); CACT, carnitine-acylcarnitine translocase deficiency (#212138); Cbl, cobalamin deficiency (complementation group); CPT-I, carnitine palmitoyltransferase I deficiency (#255120); CPT-II, carnitine palmitoyltransferase II deficiency (#255110); CUD, carnitine uptake defect (#212140); EE, ethylmalonic encephalopathy (#602473); FIGLU, formiminoglutamic aciduria (#229100); IBG, isobutyryl-CoA dehydrogenase deficiency (#611283); IVA, isovaleryl-CoA dehydrogenase deficiency (#243500); HMG, 3-hydroxy-3-methylglutaric aciduria (#246450); LCHAD, long-chain L-3-Hydroxy dehydrogenase deficiency (#609016); MADD, multiple acyl-CoA dehydrogenase deficiency (#231680); MCAD, medium-chain acyl-CoA dehydrogenase deficiency (#607008); MCD, holocarboxylase synthetase deficiency (#253270); MUT, methylmalonic aciduria (#251000, 251100, 251110); PBD, peroxisome biogenesis disorder (complementation group); PROP, propionic aciduria (#606054); SCAD, short-chain acyl-CoA dehydrogenase deficiency (#201470); TFP, trifunctional protein deficiency (#609015); VLCAD, very long-chain acyl-CoA dehydrogenase deficiency (#201475).
Table 2. Potential impact of metabolite instability on the interpretation of carnitine and acylcarnitine ratios.

| Molar Ratio | Disorder a | Retrospective Analysis of IEMs | Validation Studies for NBS Programs |
|-------------|------------|-------------------------------|------------------------------------|
|             |            | Risk Category | Potential Effect on Cutoff Target |          |
| C0/(C16 + C18) (low) | CPT-II, CACT | False-negative | Too high |
| C0/(C16 + C18) (high) | CPT-I | False-positive | Too high |
| C3/C2      | PROP, MUT, Cbl A-D, MCD | False-positive | Too high |
| C3/C16     | PROP, MUT, Cbl A-D, CPT-I, MCD | False-negative | Too low |
| C4/C2      | SCAD, MADD, IBG, EE, FIGLU b | False-negative | Too high |
| C4/C3 (low) | MCD, Cbl A-D, PROP | False-negative | Too high |
| C4/C3 (high) | EE, IBG, FIGLU b, MADD, SCAD | False-positive | Too high |
| C4/C8      | IBG, SCAD, EE, FIGLU b | None, similar percent decay of the involved acylcarnitine species | |
| C5/C2      | IVA, MADD, 2MBG, EE | False-positive | Too high |
| C5/C3 (low) | MCD, MUT, Cbl A-B, PROP | False-negative | Too high |
| C5/C3 (high) | IVA, MADD, EE, 2MBG | False-positive | Too high |
| C8/C2      | MCAD, MADD | False-positive | Too high |
| C8/C10     | MCAD | None, similar percent decay of the involved acylcarnitine species | |
| C14:1/C2   | VLCAD, MADD, LCHAD/TFP | False-positive | Too high |
| C14:1/C10  | VLCAD | Appears negligible, negative statistical trend, but no visual trend and similar percent decay of the involved acylcarnitine species | |
| C14:1/C16  | VLCAD, MADD, LCHAD/TFP | None, similar percent decay of the involved acylcarnitine species | |

The potential consequences associated with (1) the interpretation of retrospectively analysed carnitine and acylcarnitine ratios in DBS upon long-term storage at room temperature for the detection of IEMs, and (2) using control DBS stored at room temperature for validation studies on cut-off targets for NBS programs. Shaded rows represent the ratios that appear robust for the metabolite instability. The percent decays were defined as similar if the absolute difference in the estimated percent decays was <5%. The C14:1/C12:1 ratio was excluded from analysis because of infinite values in >50% of the data entries. a See caption of Table 1 for the defined abbreviations. b FIGLU is only associated with a high C4-carnitine when butylation is applied.
4. Discussion

Since the development of MS/MS analysis, several studies have reported on the instability of acylcarnitines upon long-term storage at room temperature. However, limited data are available on the decay in original samples, and the impact on acylcarnitine ratios and the associated risks of using common cut-off values for the interpretation of acylcarnitine profiles, have never been systematically assessed [12–15]. In this study, upon long-term storage at room temperature, we found a decrease in the measured concentrations of short-, medium-, and long-chain acylcarnitines of saturated and unsaturated fatty acids, while free carnitine increased. The total carnitine concentration remained similar throughout the years of storage. Likely, the acylcarnitine species are hydrolysed to free carnitine upon long-term storage at room temperature. The different decay rates of acylcarnitine species have a substantial impact on many molar ratios. In fact, only the C4/C8-, C8/10-, and C14:1/C16-carnitine ratios, and C14:1/C10-carnitine ratio, appeared robust for the metabolite instability.

In the case of retrospective, diagnostic analysis, metabolite instability may provoke false-positive and false-negative test results. Feasible identification of IEMs depends on the stability of the disease-related metabolite combined with its initial concentration and the significance of the elevation of the characteristic metabolite to the corresponding cut-off value. For many acylcarnitine biomarkers, at least the 1st to 10th percentile of the disorder range (or the 90th to 100th percentile in case of low cut-off targets) overlaps with reference intervals for the healthy population [3]. This interference, and thus the likelihood of overlooking an IEM, increases upon greater metabolite instability. Based on our results, the most adverse effects for reliable detection are expected for IEMs associated with accumulations of C3- and C5OH + C4DC-carnitine and free carnitine (e.g., propionic aciduria and methylmalonic aciduria; and 3-methylcrotonyl-CoA carboxylase deficiency, 3-hydroxy-3-methylglutaric aciduria, holocarboxylase synthetase deficiency, beta-ketothiolase deficiency; carnitine palmitoyltransferase I deficiency), and in case molar ratios are used as a primary screening test such as C14:1/C2, C0/(C16 + C18) and (C16/C18:1)/C2 (e.g., very long-chain acyl-CoA dehydrogenase deficiency; carnitine palmitoyltransferase I deficiency; and carnitine palmitoyltransferase II deficiency, carnitine-acylcarnitine translocase deficiency). Additionally, since >75% of the C5DC-carnitine measurements were below the detection limit, there appears to be a considerable impact on the retrospective diagnosis of glutaric aciduria type I. The detection of a carnitine uptake defect seems complicated by the substantial rise in free carnitine, but the sum of acylcarnitines (and free carnitine) may still enable the diagnosis [13]. In line with previous studies, the impact of metabolite instability appears relatively limited for the detectability of IEMs associated with saturated medium- and long-chain acylcarnitine accumulations, and when compared to the degradation of galactose-1-phosphate uridyltransferase and biotinidase activities [13,20]. In case of retrospective, diagnostic analysis, examination of the complete acylcarnitine profile may allow for an estimate of the metabolite instability. This would improve the interpretation of potential deviations and could reveal outliers that would otherwise not have been discovered. Especially in areas where the NBS panel is small and/or diagnostic resources are limited, this may be relevant. For diagnostic, retrospective cohort studies, we recommend including control DBS.

Caution is warranted when control DBS stored at room temperature are used for validation studies of NBS programs, because of the risk on incorrect estimation of reference ranges and cut-off targets. This particularly applies when, given their rarity, the storage conditions for samples of IEM cases for comparison analysis are different (e.g., frozen, different storage time). For validation studies, we therefore advocate using fresh control samples and comparing them to carefully stored samples of IEM cases and controls. Additionally, we emphasize the importance of repeated re-evaluation of a metabolite’s cut-off target after its introduction to the NBS panel.

Metabolite stability is affected by storage conditions. Increased temperature, humidity and sunlight exposure are known to influence sample integrity. This also accounts for other analytes used in NBS programs, such as amino acids, endocrine and enzyme markers [13,16,20–22]. Our results emphasize the importance of obtaining background information on a sample’s storage conditions.
Whereas storage at room temperature over a two-year period results in substantial changes in the concentrations of several acylcarnitine and amino acid species, these changes are attenuated or not present upon storage at $-20$ or $-80$ °C [16]. To minimize metabolite instabilities, DBS storage at low humidity (<30%) and under frozen conditions ($\leq -20$ °C) is recommended [13,16,20,22,23]. Moreover, during transport, the temperature and humidity should preferentially be minimized as much as possible [20]. Additionally, for optimal interpretation, the condition of the patient at the time of sample collection needs to be taken into account. For example, the subject’s age, metabolic stress and post-mortem sample obtainment can have a considerable impact on a metabolite profile [9,24].

Some study limitations deserve discussion. First, the initial acylcarnitine profiles are unknown due to the required anonymization procedures. This limited calculation of the true percent decays, which were instead estimated from the median concentrations in 2017. Second, there is a variation in the stability data because (1) the exact storage time of the individual DBS is unknown due to the required anonymization, and (2) the longitudinal timing of our analyses. There is evidence that suggests a more rapid degradation during the first months of storage at room temperature, which eventually slows down [12,13]. Therefore, the total decay might even be larger than the presented estimations, especially since the samples in our cohort were stored in a refrigerator without silica during the first year. Third, disparity in DBS quality and punch location are also important contributors to variation in analyte concentrations [25]. Fourth, it is unknown whether the efficiency of extraction of metabolites from filter paper cards changes upon the long-term storage of DBS. Possible effects on extractability do, however, not invalidate our findings, as the potential consequences coincide with the impact of metabolite instability. Finally, we had no access to NBS samples of diagnosed patients that were stored under the same conditions in order to validate the claimed risks presumably associated with the detection of IEMs in DBS upon long-term storage at room temperature.

In conclusion, acylcarnitine profiles in DBS stored at room temperature are subject to metabolite instability. In case of diagnostic, retrospective cohort studies, we recommend including control DBS. For validation studies, we recommend using fresh samples and to repeatedly re-evaluate cut-off targets.

Supplementary Materials: The following are available online at http://www.mdpi.com/2409-515X/6/4/83/s1. Table S1. The inter-assay precision per acylcarnitine species. Table S2. The estimated decay rates of free carnitine and acylcarnitine species upon long-term storage.

Author Contributions: Conceptualization, W.J.v.R., P.C.J.I.S., T.G.J.D., and M.R.H.-F.; Methodology, W.J.v.R., P.C.J.I.S., T.G.J.D., and M.R.H.-F.; Validation, W.J.v.R., Y.Ö., K.B., F.H.v.d.S., and M.R.H.-F.; Formal Analysis, W.J.v.R., Y.Ö., K.B., F.H.v.d.S., and M.R.H.-F.; Investigation, W.J.v.R., T.G.J.D., M.R.H.-F.; Resources, W.J.v.R., P.C.J.I.S., Y.Ö., K.B., F.H.v.d.S., T.G.J.D. and M.R.H.-F.; Data Curation, W.J.v.R., T.G.J.D., and M.R.H.-F.; Writing—Original Draft Preparation, W.J.v.R., T.G.J.D., and M.R.H.-F.; Writing—Review and Editing, W.J.v.R., P.C.J.I.S., K.B., F.H.v.d.S., T.G.J.D., and M.R.H.-F.; Visualization, W.J.v.R., T.G.J.D., M.R.H.-F.; Supervision, T.G.J.D., and M.R.H.-F.; Project Administration, W.J.v.R., T.G.J.D., and M.R.H.-F.; Funding Acquisition, W.J.v.R., T.G.J.D., M.R.H.-F. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Ubbo Emmius Fonds-Junior Scientific Masterclass Talent Grant, grant number 154 315, and Alfasigma Nederland BV, grant number O3017. The MD/PhD scholarship of Willemijn J. van Rijt is funded by the Junior Scientific Masterclass from the University of Groningen, University Medical Center Groningen (MD/PhD 15-30).

Acknowledgments: The authors would like to thank the members of the Dutch Research Committee on Neonatal Screening (WONHS in Dutch) at the National Institute for Public Health and the Environment (RIVM in Dutch), for their approval of the usage of neonatal dried blood spots for this study and their input on the study protocol. A. Koller is gratefully acknowledged for his valuable contribution to the data analysis. The financial support for this research by Alfasigma Nederland BV, the Junior Scientific Masterclass and the Ubbo Emmius Fonds is gratefully acknowledged.

Conflicts of Interest: The authors declare no conflict of interest. The sources of funding had no role in the design, execution, interpretation, or writing of the study.
Abbreviations

DBS  Dried blood spot
IEM  Inborn errors of metabolism
MS/MS  Tandem mass spectrometry
NBS  Newborn bloodspot screening

References

1. Millington, D.S.; Kodo, N.; Norwood, D.L.; Roe, C.R. Tandem mass spectrometry: A new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. *J. Inherit. Metab. Dis.* **1990**, *13*, 321–324. [CrossRef]

2. Chace, D.H.; Kalas, T.A.; Naylor, E.W. Use of Tandem Mass Spectrometry for Multianalyte Screening of Dried Blood Specimens from Newborns. *Clin. Chem.* **2003**, *49*, 1797–1817. [CrossRef]

3. McHugh, D.M.; Cameron, C.A.; Abdennur, J.E.; Abdulrahman, M.; Adair, O.; Al Nuaimi, S.A.; Åhlman, H.; Allen, J.J.; Antonozzi, I.; Archer, S.; et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project. *Genet. Med.* **2011**, *13*, 230–254. [CrossRef]

4. Therrell, B.L.; Padilla, C.D.; Loeber, J.G.; Kneisser, I.; Saadallah, A.; Borrajo, G.J.; Adams, J. Current status of newborn screening worldwide: 2015. *Semin. Perinatol.* **2015**, *39*, 171–187. [CrossRef]

5. Rothwell, E.; Johnson, E.P.; Riches, N.; Botkin, J.R. Secondary research uses of residual newborn screening dried bloodspots: A scoping review. *Genet. Med.* **2018**, *21*, 1469–1475. [CrossRef]

6. Programmacommissie Neonatale Hielprikscreening. Draaiboek Hielprikscreening. Available online: https://draaiboekhielprikscreening.rivm.nl (accessed on 18 May 2020).

7. Van Rijt, W.J.; Koolhaas, G.D.; Bekhof, J.; Fokkema, M.R.H.; De Koning, T.J.; Visser, G.; Schielen, P.C.J.I.; Van Spronsen, F.J.; Derks, T.G.J. Inborn Errors of Metabolism That Cause Sudden Infant Death: A Systematic Review with Implications for Population Neonatal Screening Programmes. *Neonatology* **2016**, *109*, 297–302. [CrossRef]

8. Boles, R.G.; Buck, E.A.; Blitzer, M.G.; Platt, M.S.; Cowan, T.M.; Martin, S.K.; Yoon, H.-R.; Madsen, J.A.; Reyes-Mugica, M.; Rinaldo, P. Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. *J. Pediatr.* **1998**, *132*, 924–933. [CrossRef]

9. Chace, D.H.; DiPerna, J.C.; Mitchell, B.L.; Sgroi, B.; Hofman, I.F.; Naylor, E.W. Electrospray Tandem Mass Spectrometry for Analysis of Acylcarnitines in Dried Postmortem Blood Specimens Collected at Autopsy from Infants with Unexplained Cause of Death. *Clin. Chem.* **2001**, *47*, 1166–1182. [CrossRef]

10. Green, A.; Preece, M.A.; Hardy, D. More on the Metabolic Autopsy. *Clin. Chem.* **2002**, *48*, 964–965. [CrossRef]

11. Barendsen, R.W.; Dijkstra, I.M.E.; Visser, W.F.; Alders, M.; Bliek, J.; Boelen, A.; Bouva, M.J.; Van Der Crabben, S.N.; Elsinghorst, E.; Van Gorp, A.G.M.; et al. Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor. *Front. Cell Dev. Biol.* **2020**, *8*. [CrossRef]

12. Johnson, D.W.; Trinh, M.-U. Stability of malonylcarnitine and glutarylcarnitine in stored blood spots. *J. Inherit. Metab. Dis.* **2004**, *27*, 789–790. [CrossRef]

13. Fingerhut, R.; Ensenaure, R.; Röschinger, W.; Arnecke, R.; Olgemöller, B.; Roscher, A.A. Stability of Acylcarnitines and Free Carnitine in Dried Blood Samples: Implications for Retrospective Diagnosis of Inborn Errors of Metabolism and Neonatal Screening for Carnitine Transporter Deficiency. *Anal. Chem.* **2009**, *81*, 3571–3575. [CrossRef]

14. Santer, R.; Fingerhut, R.; Lässker, U.; Wightman, P.J.; Fitzpatrick, D.R.; Olgemöller, B.; Roscher, A.A. Tandem Mass Spectrometric Determination of Malonylcarnitine: Diagnosis and Neonatal Screening of Malonyl-CoA Decarboxylase Deficiency. *Clin. Chem.* **2003**, *49*, 660–662. [CrossRef]

15. Strnadova, K.A.; Holub, M.; Mühl, A.; Heinze, G.; Ratschmann, R.; Mascher, H.; Stöckler-Ipsiroglu, S.; Waldhauser, F.; Votava, F.; Lebl, J.; et al. Long-Term Stability of Amino Acids and Acylcarnitines in Dried Blood Spots. *Clin. Chem.* **2007**, *53*, 717–722. [CrossRef]

16. Prentice, P.; Turner, C.; Wong, M.C.; Dalton, R.N. Stability of metabolites in dried blood spots stored at different temperatures over a 2-year period. *Bioanalysis* **2013**, *5*, 1507–1514. [CrossRef]
17. Reed, A.H.; Henry, R.J.; Mason, W.B. Influence of Statistical Method Used on the Resulting Estimate of Normal Range. *Clin. Chem.* 1971, 17, 275–284. [CrossRef]

18. Wayne, P.A. CLSI Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; CLSI Document EP28-A3C. In *Approved Guideline*, 3rd ed.; Clinical Laboratory Standards Institute: Wayne, PA, USA, 2010; p. 72.

19. Derks, T.G.J.; Boer, T.S.; Van Assen, A.; Bos, T.; Ruiter, J.H.; Waterham, H.R.; Niezen-Koning, K.E.; Wanders, R.J.A.; Rondeel, J.M.M.; Loeber, J.G.; et al. Neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in The Netherlands: The importance of enzyme analysis to ascertain true MCAD deficiency. *J. Inherit. Metab. Dis.* 2008, 31, 88–96. [CrossRef]

20. Adam, B.W.; Hall, E.; Sternberg, M.; Lim, T.; Flores, S.; O’Brien, S.; Simms, D.; Li, L.; De Jesus, V.; Hannon, W. The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States. *Clin. Biochem.* 2011, 44, 1445–1450. [CrossRef]

21. Golbahar, J.; Altayab, D.D.; Carreon, E. Short-Term Stability of Amino acids and Acylcarnitines in the Dried Blood Spots Used to Screen Newborns for Metabolic Disorders. *J. Med. Screen.* 2014, 21, 5–9. [CrossRef]

22. Han, J.; Higgins, R.; Lim, M.D.; Lim, K.; Yang, J.; Borchers, C.H. Short-Term Stabilities of 21 Amino Acids in Dried Blood Spots. *Clin. Chem.* 2018, 64, 400–402. [CrossRef]

23. Michopoulos, F.; Theodoridis, G.; Smith, C.J.; Wilson, I.D. Metabolite profiles from dried blood spots for metabonomic studies using UPLC combined with orthogonal acceleration ToF-MS: Effects of different papers and sample storage stability. *Bioanalysis* 2011, 3, 2757–2767. [CrossRef]

24. Van Rijt, W.J.; Van Der Ende, R.M.; Volker-Touw, C.M.; Van Spronsen, F.; Derks, T.G.; Heiner-Fokkema, M.R. Changes in pediatric plasma acylcarnitines upon fasting for refined interpretation of metabolic stress. *Mol. Genet. Metab.* 2019, 127, 327–335. [CrossRef]

25. George, R.S.; Moat, S.J. Effect of Dried Blood Spot Quality on Newborn Screening Analyte Concentrations and Recommendations for Minimum Acceptance Criteria for Sample Analysis. *Clin. Chem.* 2016, 62, 466–475. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).